Navigation Links
5th Annual Summit to Feature New Stem Cell Therapies
Date:1/8/2010

WAYNE, Pa., Jan. 8 /PRNewswire/ -- Six new stem cell therapies, all forecast to reach physicians in 2010, will be featured at the 5th Annual Stem Cell Summit on February 16 in New York City. These new therapies include allograft products, innovative forms of autologous stem cell technologies, and at least one FDA-approved stem cell drug. New studies showing rehydration of the disc nucleus, regeneration of new heart muscle and others are also on the agenda.

The Stem Cell Summit is an annual gathering of stem cell and biomaterial company executives, scientists and investors to explore the therapeutic applications of stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities within the space. The Summit features 35 corporate presentations, a scientific panel, separate tracks for stem cell tools & instruments, and a closing reception. It is an intensive one-day event held at Bridgewaters in New York City's historic South Street Seaport.


                  The presenting stem cell companies include:

    Aastrom Biosciences, Inc.     INCELL Corporation, LLC
    AllCells, LLC                 International Stem Cell Corp.
    AlloSource                    Lonza Group Ltd.
    Aldagen, Inc.                 MaxCyte, Inc.
    ArunA Biomedical, Inc.        Mesoblast Limited
    Athersys, Inc.                Novocell, Inc.
    BioE Inc.                     Osiris Therapeutics, Inc.
    Cardiogenesis Corp.           Pluristem Therapeutics Inc.
    Cellerix, S.A.                ProChon Biotech, Ltd.
    Celtigen Therapeutics, LLC    Progenitor Cell Therapy, Inc.
    Core Dynamics Ltd.            SpineSmith Partners LP
    Cytori Therapeutics, Inc.     Stematix, Inc.
    Gamida Cell Ltd.              Stemina Biomarker Discovery, Inc.
    Garnet BioTherapeutics, Inc.  TiGenix NV
    Genzyme Biosurgery            Tissue Genesis, Inc.
    Glycosan BioSystems, Inc.     TxCell SA
    Harvest Technologies Corp.    Vet-Stem, Inc.
    Histogen, Inc.

In addition to the company and scientific presentations, Robin R. Young, CFA, a leading medical technologies analyst, will deliver his updated 10-year market forecast for the industry. "In 2009, the number of new market entrants was notable, but there were some difficulties with regard to clinical trials. Nevertheless, sales of stem cell therapies continue to grow extremely rapidly in the United States. We now estimate that revenues from stem cell therapies will surpass $2.5 billion by 2015 and that the industry will support a $10 billion valuation," said Young.


                 5th Annual Stem Cell Summit Facts at a Glance

    When:            Tuesday, February 16, 2010

    Where:           Bridgewaters
                     11 Fulton Street
                     New York City

    Admission:       $1,200 advance registration by January 31, 2010
                     $1,500 (February 1 - 16, 2010)

    Information:     A detailed agenda and online registration are
                     available at www.stemcellsummit.com.


    Contact:          Lisa Carpenter
                      RRY Publications, LLC
                      877-817-6450
                      lisa@ryortho.com


SOURCE Stem Cell Summit

RELATED LINKS
http://www.stemcellsummit.com

'/>"/>

SOURCE Stem Cell Summit
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
2. Sinovac Announces Postponement of Annual General Meeting
3. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
6. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
7. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
8. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Allos Therapeutics to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference
11. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and technical consulting, provides a free webinar on Performing Quality Investigations: ... 2016 at 12pm CT at no charge. , Incomplete investigations are still a ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):